Concerns are rising among U.S. Ophthalmologists regarding a novel vision therapy developed in China aimed at slowing the progression of myopia, or nearsightedness, in children. The treatment involves low-level red light laser exposure to the back of the eye. A recent study, slated for publication in JAMA Ophthalmology in 2026 (DOI: 10.1001/jamaophthalmol.2025.5660), found that two out of four devices tested exceeded U.S. Safety limits for medical lasers.
Myopia is a growing global health concern, particularly in East Asia. In China, an estimated 80% of children are now nearsighted, a dramatic increase in recent decades. Experts attribute this surge to factors like increased screen time, reduced outdoor activity, and intensive academic pressure, all of which contribute to prolonged near work. The eye responds to this sustained close focus by elongating, leading to the development of myopia. This elongation stretches the retina, increasing the risk of serious eye conditions later in life, such as retinal detachment, glaucoma, and myopic maculopathy.
The Promise and Peril of Low-Level Laser Therapy
The Chinese-developed therapy, often referred to as “orthokeratology light therapy,” aims to address this issue by modulating eye growth. The theory is that specific wavelengths of red light can influence the biochemical processes within the retina, potentially slowing down the rate of axial elongation – the lengthening of the eyeball. While the concept is intriguing, the study published in JAMA Ophthalmology raises significant safety questions. Researchers evaluated four devices marketed for this purpose and discovered that two of them emitted laser energy levels that surpassed permissible limits established by the U.S. Food and Drug Administration (FDA) for similar medical devices. These higher energy levels could potentially cause retinal damage, although the long-term effects remain unclear.
“We need to be cautious about adopting therapies without rigorous testing and adherence to established safety standards,” says Dr. Emily Carter, a pediatric ophthalmologist at the University of California, San Francisco, who was not involved in the study. “The potential benefits of slowing myopia progression must be carefully weighed against the risks of unintended harm.” The FDA has not yet approved any of these devices for use in the United States, and currently, they are not legally available for sale.
A Growing Epidemic: Understanding the Rise of Myopia
The global rise in myopia is a complex phenomenon. While genetics play a role, environmental factors are increasingly recognized as major contributors. Research consistently demonstrates a strong correlation between time spent outdoors and a reduced risk of developing myopia. Exposure to natural light stimulates the release of dopamine in the retina, which is believed to inhibit excessive eye growth. Conversely, prolonged near work, such as reading, using computers, and smartphones, encourages the eye to elongate. The American Academy of Ophthalmology provides comprehensive information on myopia and its prevention.
The situation is particularly acute in East Asian countries like China, South Korea, and Japan, where academic demands are high and outdoor play is often limited. In these regions, myopia often begins at a very young age, and the rate of progression is faster than in Western countries. This has led to a search for innovative interventions, including low-level laser therapy, to combat the epidemic.
Current Treatment Options for Myopia Control
Currently, several evidence-based strategies are available for managing myopia progression. These include:
- Atropine eye drops: Low-dose atropine drops can slow myopia progression, but they may cause side effects such as blurred vision and light sensitivity.
- Multifocal contact lenses: These lenses have different powers in different zones, which can support to reduce eye strain and slow elongation.
- Orthokeratology (Ortho-K): These specially designed rigid gas permeable contact lenses are worn overnight to temporarily reshape the cornea, reducing nearsightedness during the day.
- Increased outdoor time: Encouraging children to spend at least 90 minutes outdoors each day can significantly reduce their risk of developing myopia.
These methods, while effective, require consistent adherence and regular monitoring by an eye care professional. The appeal of a non-invasive, relatively simple treatment like low-level laser therapy is understandable, but the recent findings underscore the importance of prioritizing safety and efficacy.
Looking Ahead: Further Research and Regulatory Scrutiny
The study in JAMA Ophthalmology is expected to prompt increased scrutiny from regulatory agencies, including the FDA, regarding the safety and efficacy of these devices. Further research is needed to determine the optimal wavelengths, dosages, and treatment protocols for low-level laser therapy, as well as to assess the long-term effects on retinal health. Researchers also need to investigate whether variations in device manufacturing and quality control contribute to the safety concerns.
For now, ophthalmologists recommend sticking to established myopia control strategies and exercising caution when considering unproven therapies. Parents concerned about their child’s vision should consult with a qualified eye care professional to discuss the best course of action. The next step in evaluating these devices will likely involve more comprehensive clinical trials conducted under strict regulatory oversight, with a focus on ensuring patient safety and demonstrating genuine efficacy.
This is a developing story, and we will continue to provide updates as more information becomes available. If you have concerns about your or your child’s vision, please consult with a qualified healthcare provider.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
